TY - JOUR
T1 - Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug
AU - Vega, María Celeste
AU - Rolón, Miriam
AU - Montero-Torres, Alina
AU - Fonseca-Berzal, Cristina
AU - Escario, José Antonio
AU - Gómez-Barrio, Alicia
AU - Gálvez, Jorge
AU - Marrero-Ponce, Yovani
AU - Arán, Vicente J.
N1 - Funding Information:
Partial support of this work by the Spanish Ministries of Science and Innovation (MICINN, ref. SAF2009-10399) and Foreign Affairs and Cooperation (MAEC-AECID, ref. A/030156/10), and by Universidad Complutense de Madrid-Banco Santander Central Hispano (UCM-BSCH, ref. GR35/10–911120) is gratefully acknowledged. Y. M.-P. thanks the program ‘Estades Temporals per a Investigadors Convidats’ for a fellowship to work at Valencia University (2012) and C. F.-B. acknowledges Moncloa Campus of International Excellence (UCM-UPM & CSIC) for a PICATA predoctoral fellowship.
PY - 2012/12
Y1 - 2012/12
N2 - Chagas disease chemotherapy, currently based on only two drugs, nifurtimox and benznidazole, is far from satisfactory and therefore the development of new antichagasic compounds remains an important goal. On the basis of antichagasic properties previously described for some 1,2-disubstituted 5-nitroindazolin-3- ones (21, 33) and in order to initiate the optimization of activity of this kind of compounds, we have prepared a series of related analogs (22-32, 34-38, 58 and 59) and tested in vitro these products against epimastigote forms of Trypanosoma cruzi. 2-Benzyl-1-propyl (22), 2-benzyl-1-isopropyl (23) and 2-benzyl-1-butyl (24) derivatives have shown high trypanocidal activity and low unspecific toxicity. Other indazole derivatives with different substitution patterns (1-substituted 3-alkoxy-1H-indazoles and 2-substituted 3-alkoxy-2H-indazoles), arising from the synthetic procedures used to prepare the mentioned indazolinones, have moderate to low effectiveness. The exploration of SAR information using the concept of an activity landscape has been carried out with SARANEA software. We have also searched for structural similarities between 225 known antiprotozoan drugs and compound 22. The results confirm that compounds 22-24 constitute promising leads and that 5-nitroindazolin-3-one system is a novel anti-T. cruzi scaffold which may represent an important therapeutic alternative for the treatment of Chagas disease.
AB - Chagas disease chemotherapy, currently based on only two drugs, nifurtimox and benznidazole, is far from satisfactory and therefore the development of new antichagasic compounds remains an important goal. On the basis of antichagasic properties previously described for some 1,2-disubstituted 5-nitroindazolin-3- ones (21, 33) and in order to initiate the optimization of activity of this kind of compounds, we have prepared a series of related analogs (22-32, 34-38, 58 and 59) and tested in vitro these products against epimastigote forms of Trypanosoma cruzi. 2-Benzyl-1-propyl (22), 2-benzyl-1-isopropyl (23) and 2-benzyl-1-butyl (24) derivatives have shown high trypanocidal activity and low unspecific toxicity. Other indazole derivatives with different substitution patterns (1-substituted 3-alkoxy-1H-indazoles and 2-substituted 3-alkoxy-2H-indazoles), arising from the synthetic procedures used to prepare the mentioned indazolinones, have moderate to low effectiveness. The exploration of SAR information using the concept of an activity landscape has been carried out with SARANEA software. We have also searched for structural similarities between 225 known antiprotozoan drugs and compound 22. The results confirm that compounds 22-24 constitute promising leads and that 5-nitroindazolin-3-one system is a novel anti-T. cruzi scaffold which may represent an important therapeutic alternative for the treatment of Chagas disease.
KW - Antiprotozoan agents
KW - Chagas disease
KW - Cluster analysis
KW - Cytotoxicity
KW - Indazoles
KW - Structure-activity relationships
UR - http://www.scopus.com/inward/record.url?scp=84868242243&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2012.10.009
DO - 10.1016/j.ejmech.2012.10.009
M3 - Artículo
C2 - 23124218
AN - SCOPUS:84868242243
SN - 0223-5234
VL - 58
SP - 214
EP - 227
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
ER -